Last year we were desperate to get my Father into a liver
Last year we were desperate to get my Father into a liver cancer trial. (Liver cancer is always fatal.) He was accepted into a study using inter-lesional injections and one of the things we were told was that if he responded favorably, he could get additional injections if necessary until his situation resolved, one way or the other. I agree that sounds somewhat illogical since it would seem to indicate that the study parameters were somehow open-ended. (i.e. The injections might have decreased the tumor burden but not illiminate it, thus necessitating continuing injections for the rest of his life. Such an outcome would still be a huge improvement over the current standard of care but how could they report the results so that they could advance to later stage trials?) Unfortunately my Father fell and hit his head. By the time he recovered from the brain bleed his cancer had grown to the point that he was no longer eligible for the trial. We lost him a couple of months later.
I can only assume that such eventualities were somehow covered in the original study parameters. And I certainly hope that anyone who was being helped by Kevetrin is still able to continue taking it. The fact that those who were accepted into the Kevetrin trial at lower doses were allowed to continue in the trial and participate at higher doses if they wished, gives me hope that the study parameters did not call for cutting them off cold turkey.
"Without getting a direct answer from the company one can only make an assumption. Mine currently, be it right or wrong, is that drugs used in a STUDY that have not yet been FDA approved cannot be given LEGALLY to anyone outside an authorized study. That even includes participants in a now close PHASE trial that have and could benefit from continued use of a developmental drug. That may seem a bit harsh but laws and regulations are in place to protect us even if at times they do not. This is of course an OPINION as I am not up on FDA regulations. Am hoping I am missing something." - NotRichYet2
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Professor Plaxco’s Dynamic Role at Nutromics Some folks start their day with breakfast and coffee, but Nutromics is grabbing headlines by introducing Professor Kevin Plaxco as the new Chief Scientific Officer. This strategic shift, made public on September 7, 2026, signals Nutromics’ ambition to amplify its DNA-based sensing footprint. As they gear up to launch their...
Continue Reading
AI Transformation: Hard Reality or Strategic Opportunity? The future of work. That’s what everyone’s buzzing about lately, isn’t it? AI poised to shake every nook and cranny. You're either riding the wave or getting crushed by it. It’s no longer some distant prospect—the challenge is right here, now. Come September 23, Zellis Connect 2026 is plunging headfirst...
Continue Reading
Change Is Brewing in Europe's Telecom Markets Seems like Europe's telco scene is simmering. Over half of consumers in major European markets are giving their mobile providers the side-eye, ready to jump ship. That's putting the heat on operators who once banked on loyalty programs to keep their customer base intact. Diverse Loyalty Challenges Across Europe What's...
Continue Reading
Hyundai Drives Into Europe's Football Arena Football fever just turned electric with Hyundai allying itself with the UEFA Champions League. We're not talking about sidelines. We're smack dab in the center field of a multi-year partnership starting with the 2026/27 season. Folks, if you think this is just Hyundai shaking hands for brand exposure, think again. This is...
Continue Reading
EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...
Continue Reading
D-Wave Quantum Under Legal Microscope Alright, folks, let's dive headfirst into some dicey financial waters with D-Wave Quantum Inc. (NASDAQ: QBTS). This quantum computing company is finding itself in a bit of a pickle following some rough second-quarter results that left investors scratching their heads. If you bought into the hype and are feeling the sting in your...
Continue Reading
Under the shadows of Manhattan's skyline, something more than a regular service took shape. The New Yorker Hotel hosted an impassioned gathering of the Family Federation for World Peace and Unification. These folks weren't just saying their prayers; they were making a call—loud and resonant—for the release of Dr. Hak Ja Han. The Power of Collective Voices Gathering in...
Continue Reading
Revolution in Packaging: Southeast Asia Steps Up Get ready for a wake-up call in the world of packaging, folks; the Southeast Asian market is taking a sharp turn toward sustainability and technological advancement, as highlighted by WEPSEA 2026's recent wrap-up in Shanghai. Far from a mere exhibition, this gathering served as the crucible for change, where old-school...
Continue Reading
The New Gold Standard in Safety for Small EVs Hop into your favorite auto forum and you'll hear more than a buzz—it's a full-blown ruckus. The reason? GAC’s AION UT just nabbed a 2026 Euro NCAP Five-Star Safety Rating. Now, this isn’t just another accolade in a crowded trophy room; it’s a statement, a seismic shift in how small electric vehicles stack up in terms...
Continue Reading
Cuffless BP Monitoring: Changing the Game for AF and HF Ever thought a finger ring could revolutionize blood pressure monitoring? Well, welcome to the future—Sky Labs' ring-type CART monitor has just rocked the scene at the ESC Congress 2026 in Munich. This isn't sci-fi, folks; it's where health tech meets reality, and it's shaking the very foundations of how we manage...
Continue Reading
Top 5 Most Recently Viewed Articles
Lynkwell Amplifies Growth Plans for North American Expansion Lynkwell, a leading player in energy infrastructure, is set to embark on an exciting journey into 2025. With a focus on meeting the growing demands of the evolving electric vehicle (EV) market, Lynkwell is making significant investments to enhance its capabilities and expand its footprint across North America....
Continue Reading
Overview of Recent Trends in Private Student Loans In the recent semi-annual Private Student Loan Report released by Enterval Analytics, insights into the current status of private student loans reveal a stable repayment landscape. Since Enterval focuses on the private student loan market, their findings shed light on how borrowers are adapting their financial strategies...
Continue Reading
StemCyte's Major Achievement in Cord Blood Therapy StemCyte has made significant strides in regenerative medicine, specifically with its Hematopoietic Progenitor Cell (HPC) Cord Blood therapy. The company recently announced that it has received the Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) aimed at treating...
Continue Reading
Novo Nordisk's Significant Job Cuts Novo Nordisk, a leading pharmaceutical company in diabetes care, has announced a major workforce reduction, cutting 9,000 jobs, which amounts to about 11.5% of its employees. This decision reflects the intense market pressure the company faces from its competitor, Eli Lilly. Restructuring for Financial Efficiency The restructuring...
Continue Reading
Elevating Research with One Helix One Helix emerges as a landmark project in life sciences, representing a new era of innovation and sustainable architecture. Located within a prominent university medical center, this facility is not just a building; it is a commitment to fostering scientific advancements. Completely leased to AstraZeneca, One Helix is designed to elevate...
Continue Reading
